MICROPORT (00853) surged more than 4%, reaching HK$11.57 by the time of writing, with a trading volume of HK$103 million. BofA Securities reiterated its "Buy" rating on MICROPORT, citing attractive risk-reward dynamics. The firm highlighted the company's diversified portfolio of high-value medical consumables, with its surgical robot business expected to become a major growth driver. BofA projects that surgical robots will contribute 19% of total revenue by 2034. The report also noted that MICROPORT's shareholder, Shanghai Industrial Group, may provide financial and operational support while addressing corporate governance. Additionally, the company is alleviating liquidity concerns and, through cost controls and divestment of non-core assets, is expected to achieve profitability starting from the first half of 2026.